Sana Biotechnology (SANA) Competitors $2.53 +0.17 (+7.20%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SANA vs. FLGT, ALLO, ORTX, SAGE, FATE, APGE, MIRM, CNTA, HRMY, and EVOShould you be buying Sana Biotechnology stock or one of its competitors? The main competitors of Sana Biotechnology include Fulgent Genetics (FLGT), Allogene Therapeutics (ALLO), Orchard Therapeutics (ORTX), Sage Therapeutics (SAGE), Fate Therapeutics (FATE), Apogee Therapeutics (APGE), Mirum Pharmaceuticals (MIRM), Centessa Pharmaceuticals (CNTA), Harmony Biosciences (HRMY), and Evotec (EVO). These companies are all part of the "medical" sector. Sana Biotechnology vs. Fulgent Genetics Allogene Therapeutics Orchard Therapeutics Sage Therapeutics Fate Therapeutics Apogee Therapeutics Mirum Pharmaceuticals Centessa Pharmaceuticals Harmony Biosciences Evotec Sana Biotechnology (NASDAQ:SANA) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, community ranking, earnings, profitability, risk, media sentiment and valuation. Is SANA or FLGT more profitable? Sana Biotechnology has a net margin of 0.00% compared to Fulgent Genetics' net margin of -59.39%. Fulgent Genetics' return on equity of -1.81% beat Sana Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Sana BiotechnologyN/A -84.22% -44.97% Fulgent Genetics -59.39%-1.81%-1.66% Which has more risk & volatility, SANA or FLGT? Sana Biotechnology has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Do institutionals & insiders hold more shares of SANA or FLGT? 88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are owned by institutional investors. 31.1% of Sana Biotechnology shares are owned by company insiders. Comparatively, 31.8% of Fulgent Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, SANA or FLGT? Fulgent Genetics has higher revenue and earnings than Sana Biotechnology. Fulgent Genetics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSana BiotechnologyN/AN/A-$283.26M-$1.40-1.81Fulgent Genetics$289.21M1.83-$167.82M-$5.52-3.13 Does the media prefer SANA or FLGT? In the previous week, Sana Biotechnology had 1 more articles in the media than Fulgent Genetics. MarketBeat recorded 5 mentions for Sana Biotechnology and 4 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 0.36 beat Sana Biotechnology's score of -0.02 indicating that Fulgent Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor SANA or FLGT? Fulgent Genetics received 227 more outperform votes than Sana Biotechnology when rated by MarketBeat users. Likewise, 60.25% of users gave Fulgent Genetics an outperform vote while only 56.67% of users gave Sana Biotechnology an outperform vote. CompanyUnderperformOutperformSana BiotechnologyOutperform Votes1756.67% Underperform Votes1343.33% Fulgent GeneticsOutperform Votes24460.25% Underperform Votes16139.75% Do analysts recommend SANA or FLGT? Sana Biotechnology currently has a consensus price target of $13.50, indicating a potential upside of 433.60%. Fulgent Genetics has a consensus price target of $28.50, indicating a potential upside of 64.93%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, equities research analysts plainly believe Sana Biotechnology is more favorable than Fulgent Genetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sana Biotechnology 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Fulgent Genetics 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryFulgent Genetics beats Sana Biotechnology on 9 of the 17 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Sana Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for SANA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SANA vs. The Competition Export to ExcelMetricSana BiotechnologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$526.91M$2.95B$5.06B$8.89BDividend YieldN/A1.90%4.97%4.06%P/E Ratio-1.8117.8689.0213.30Price / SalesN/A222.321,207.2881.01Price / CashN/A160.0839.1736.03Price / Book1.934.906.085.74Net Income-$283.26M-$41.63M$119.07M$225.93M7 Day Performance-2.32%-4.73%-1.84%-1.32%1 Month Performance-35.62%-6.53%-3.65%0.60%1 Year Performance-36.91%25.63%31.62%26.23% Sana Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SANASana Biotechnology2.2165 of 5 stars$2.53+7.2%$13.50+433.6%-41.2%$526.91MN/A-1.81328FLGTFulgent Genetics4.1478 of 5 stars$17.28+1.6%$28.50+64.9%-37.4%$519.98M$289.21M0.001,184Analyst UpgradeALLOAllogene Therapeutics2.7811 of 5 stars$2.05-3.3%$9.73+374.8%-31.4%$429.82M$90,000.00-1.31232Short Interest ↓ORTXOrchard TherapeuticsN/A$16.70flatN/AN/A$380.09M$22.66M-17.77166SAGESage Therapeutics4.2604 of 5 stars$4.91flat$12.89+162.5%-75.1%$300.36M$86.46M0.00690Analyst ForecastNews CoverageGap DownFATEFate Therapeutics3.9121 of 5 stars$2.22+1.8%$6.75+204.1%-14.6%$248.29M$63.53M0.00550Analyst UpgradeAPGEApogee Therapeutics2.241 of 5 stars$45.04-3.2%$78.50+74.3%+149.9%$2.03BN/A-18.6191MIRMMirum Pharmaceuticals4.2959 of 5 stars$43.69+3.8%$57.73+32.1%+36.1%$2.02B$186.37M0.00140Analyst RevisionCNTACentessa Pharmaceuticals4.0515 of 5 stars$16.74-0.5%$25.83+54.3%+144.7%$1.91B$6.85M0.0072HRMYHarmony Biosciences4.7841 of 5 stars$32.79+1.0%$47.00+43.3%+18.1%$1.85B$582.02M15.54200EVOEvotec1.7338 of 5 stars$5.30+2.9%$5.93+11.9%-49.7%$1.83B$845.74M0.005,061 Related Companies and Tools Related Companies FLGT Competitors ALLO Competitors ORTX Competitors SAGE Competitors FATE Competitors APGE Competitors MIRM Competitors CNTA Competitors HRMY Competitors EVO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SANA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sana Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sana Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
